A recent TriNetX analysis concluded that patients living with overweight or obesity, who were treated with semaglutide, compared to non-GLP-1 RA anti-obesity medications, had a lower risk of suicidal ideation; with the findings replicated in patients with T2D.13 This evidence concerns the gene GCG and type 2 diabetes mellitus.